14-day Premium Trial Subscription Try For FreeTry Free

Gilead Records Positive Phase III Results In HIV

03:56am, Saturday, 22'nd Jun 2024
Gilead Sciences reports positive Phase III trial results for lenacapavir, showing zero incident cases of HIV infection in the treatment group. Results suggest the potential for lenacapavir to revoluti
Support for Gilead shares sits near 57.
Gilead's (GILD) twice-yearly, subcutaneous lenacapavir has demonstrated its potential as a new tool to help prevent HIV infections with zero infections and 100% efficacy. Shares gain.
Gilead Sciences NASDAQ: GILD saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. The biopharmaceutical company revealed 100% efficacy in its P
One method of identifying which stocks to buy is to find those with price-to-earnings (P/E) ratios below their industry peers or historical averages. A low P/E suggests the stock possesses underlying
Gilead (GILD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
Gilead Sciences (GILD) surged over 8% in intraday trading Thursday as the biotech firm announced a Phase 3 trial found its injectable lenacapavir was 100% effective in preventing HIV infection in wome
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) shares added more than 8% after the pharmaceutical firm unveiled new data from a late-stage PURPOSE trial which showed its twice-yearly injectable HIV therap
Stocks are all over the place today, with the Dow confidently higher, the Nasdaq choppy, and the S&P 500 contending with a psychologically-significant level.
Gilead stock surged Thursday after its twice-annual shot proved 100% effective in preventing HIV infections in cisgender women.
Gilead's twice-yearly medicine to prevent HIV succeeded in a Phase 3 trial. None of the roughly 2,000 women in the trial who received the shot, lenacapavir, contracted HIV.
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead Sciences Inc.'s stock GILD jumped 4.5% early Thursday after the company said its experimental twice-yearly injection for HIV prevention was found 100% effective in a late-stage trial.
Gilead Sciences said on Thursday a late-stage study showed its injectable drug, lenacapavir, was more effective in preventing HIV infection in women compared to the company's existing daily pill Truva
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company'
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE